Hence, acetylcholinesterase (AChE) inhibition - action against the enzyme responsible for the breakdown of acetylcholine - is one of the most critical therapeutic treatments for boosting cholinergic neurotransmission in AD sufferers due to these mechanisms [5]. The gene discussed is ACHE; the disease is Alzheimer disease.